Find Paid Clinical Trials in New Hampshire

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in New Hampshire

Top of Directory » All Locations » United States » New Hampshire




  • A Pilot Study of Bevacizumab (Avastin) in Patients With Unresectable or Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

    Conditions:   Hemangioblastomas;   Von Hippel Lindau Disease
    Intervention:   Drug: Avastin
    Sponsors:   Dartmouth-Hitchcock Medical Center;   Genentech
    Not yet recruiting - verified November 2009

  • A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Creighton Model Effectiveness, Intentions and Behaviors Assessment (CEIBA)

    Conditions:   Pregnancy;   Fertility
    Intervention:  
    Sponsors:   University of Utah;   Department of Health and Human Services
    Recruiting - verified November 2009

  • Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Condition:   Leukemia
    Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720

    Condition:   Leukemia
    Intervention:   Other: laboratory biomarker analysis
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • ActiveStep Comparative Effectiveness Trial

    Condition:   Balance
    Interventions:   Device: ActiveStep Treadmill;   Other: Physical Therapy
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Not yet recruiting - verified November 2009

  • Levetiracetam XR in Very Heavy Drinkers

    Condition:   Alcoholism
    Interventions:   Drug: levetiracetam XR;   Drug: Sugar Pill
    Sponsor:   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    Recruiting - verified November 2009

  • A Study in Relapse Prevention of Treatment-resistant Depression

    Condition:   Treatment Resistant Depression
    Interventions:   Drug: Olanzapine and Fluoxetine combination;   Drug: Fluoxetine
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • Study of VX-770 in Cystic Fibrosis Subjects Age 12 and Older Homozygous for the F508del-CFTR Mutation

    Condition:   Cystic Fibrosis
    Interventions:   Drug: VX-770;   Drug: Placebo
    Sponsors:   Vertex Pharmaceuticals Incorporated;   Cystic Fibrosis Foundation
    Recruiting - verified November 2009

  • Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

    Conditions:   Kidney Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: gemcitabine/carboplatin;   Drug: gemcitabine/carboplatin plus BSI-201
    Sponsor:   BiPar Sciences
    Recruiting - verified November 2009

  • Abatacept Versus Adalimumab Head-to-Head

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Abatacept;   Drug: Adalimumab
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified November 2009

  • Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

    Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
    Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

    Condition:   Brain and Central Nervous System Tumors
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

    Condition:   Neuroblastoma
    Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

    Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting Tumor Samples From Patients With Gynecological Tumors

    Condition:   Cancer
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Kidney Tumors in Young Patients

    Conditions:   Kidney Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: Nonbiologic DMARDs of investigator's choice
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

    Condition:   Endometrial Cancer
    Intervention:   Drug: brivanib alaninate
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Biological: bevacizumab;   Drug: temozolomide;   Other: placebo
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

    Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
    Intervention:   Drug: zoledronic acid
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

    Condition:   Gastrointestinal Stromal Tumor (GIST)
    Intervention:   Drug: imatinib mesylate
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • AST-120 Used to Treat Mild Hepatic Encephalopathy

    Condition:   Mild Hepatic Encephalopathy
    Intervention:   Drug: AST-120
    Sponsor:   Ocera Therapeutics
    Recruiting - verified November 2009

  • VEG111485: A QTc Study of Pazopanib

    Condition:   Solid Tumor
    Interventions:   Other: Placebo for pazopanib;   Other: Placebo for moxifloxacin;   Drug: Moxifloxacin;   Drug: Pazopanib
    Sponsor:   GlaxoSmithKline
    Recruiting - verified October 2009

  • Study of Immunotherapy to Treat Advanced Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: Ipilimumab;   Drug: Placebo
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified September 2009

  • Atorvastatin Three Year Pediatric Study

    Condition:   Familial Hypercholesterolemia
    Intervention:   Drug: atorvastatin
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Phase 2 Safety & Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 vs FOLFIRI in KRAS-mutant Metastatic Colorectal Carcinoma

    Condition:   Metastatic Colorectal Cancer
    Interventions:   Other: FOLFIRI;   Biological: AMG 655;   Biological: AMG 479;   Other: Placebo
    Sponsor:   Amgen
    Recruiting - verified November 2009

  • Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

    Condition:   Carcinoma, Hepatocellular
    Intervention:   Drug: Sorafenib (Nexavar, BAY43-9006)
    Sponsor:   Bayer
    Recruiting - verified November 2009

  • Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

    Conditions:   Menopause;   Osteoporosis
    Interventions:   Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg;   Drug: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg;   Drug: bazedoxifene 20 mg;   Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg;   Drug: Placebo
    Sponsor:   Wyeth
    Recruiting - verified November 2009

  • A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

    Conditions:   Skin Cancer;   Melanoma;   Metastatic Melanoma
    Interventions:   Drug: temozolomide;   Drug: ABT-888;   Drug: Placebo
    Sponsor:   Abbott
    Recruiting - verified November 2009

  • Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients With Chronic Plaque Psoriasis (Ps)

    Condition:   Chronic Plaque Psoriasis
    Intervention:   Biological: HUMIRA® (adalimumab)
    Sponsor:   Abbott
    Recruiting - verified October 2009

  • Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients With Locally Recurrent, Stage IIIB, or Stage IV Breast Cancer

    Conditions:   Breast Cancer;   Chemotherapeutic Agent Toxicity;   Long-term Effects Secondary to Cancer Therapy in Adults;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment
    Interventions:   Biological: bevacizumab;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Inegy vs. the Doubling of Atorvastatin in High Risk Patients

    Condition:   Hypercholesterolemia
    Interventions:   Drug: Comparator: ezetimibe/simvastatin 10/40 mg;   Drug: Comparator: atorvastatin 40 mg;   Drug: Comparator: atorvastatin 20 mg
    Sponsor:   Merck
    Recruiting - verified November 2009

  • Paclitaxel and Trastuzumab and/or Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

    Condition:   Breast Cancer
    Interventions:   Biological: trastuzumab;   Drug: lapatinib ditosylate;   Drug: paclitaxel
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

    Condition:   Breast Cancer
    Interventions:   Biological: trastuzumab;   Radiation: radiation therapy
    Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • (ARTEMIS-IPF)Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

    Condition:   Idiopathic Pulmonary Fibrosis
    Intervention:   Drug: ambrisentan or sugar pill
    Sponsor:   Gilead Sciences
    Recruiting - verified November 2009

  • A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

    Condition:   Optic Neuropathy, Ischemic
    Intervention:  
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures

    Conditions:   Epilepsy, Partial, Motor;   Epilepsy, Complex Partial;   Epilepsy, Simple Partial;   Focal Motor Epilepsy
    Interventions:   Drug: carisbamate;   Drug: placebo
    Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Recruiting - verified November 2009

  • A Carotid Stenting Boston Scientific Surveillance Program

    Condition:   Carotid Artery Disease
    Interventions:   Device: Carotid WALLSTENT Monorail Endoprosthesis;   Device: FilterWire EZ™ System™
    Sponsor:   Boston Scientific Corporation
    Recruiting - verified October 2009

  • A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: ASA404 in combination with docetaxel;   Drug: Placebo in combination with docetaxel
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • Platinum Resistant Ovarian Cancer Evaluation of Doxil and EC145 Combination Therapy

    Condition:   Ovarian Cancer
    Interventions:   Drug: EC145;   Drug: pegylated liposomal doxorubicin (PLD);   Drug: EC20;   Drug: EC20
    Sponsor:   Endocyte
    Recruiting - verified October 2009

  • Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

    Condition:   Locally Advanced and/or Metastatic Renal Cell Carcinoma
    Interventions:   Drug: Sunitinib;   Drug: Pazopanib
    Sponsor:   GlaxoSmithKline
    Recruiting - verified November 2009

  • Chemotherapy and Radiation Therapy With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer

    Condition:   Head and Neck Cancer
    Interventions:   Drug: cisplatin;   Drug: vandetanib;   Radiation: radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Condition:   Advanced or Metastatic Non-Small Cell Lung Cancer
    Interventions:   Drug: ABT-869;   Drug: Placebo
    Sponsors:   Abbott;   Genentech
    Recruiting - verified October 2009

  • Study Evaluating HKI-272 in Combination With Vinorelbine in Subjects With Solid Tumors and Metastatic Breast Cancer

    Conditions:   Advanced Breast Cancer;   Advanced Malignant Solid Tumors
    Intervention:   Drug: treatment with HKI-272+ vinorelbine
    Sponsor:   Wyeth
    Recruiting - verified November 2009

  • Prospective, Randomized, Multi-Center, Comparator Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema

    Conditions:   Diabetic Retinopathy;   Diabetes Complications
    Interventions:   Procedure: Laser Treatment;   Drug: PF-04523655 high;   Drug: PF-04523655 middle;   Drug: PF-04523655 low
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

    Condition:   Carcinoma, Hepatocellular
    Interventions:   Drug: sunitinib malate;   Drug: sorafenib
    Sponsor:   Pfizer
    Recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials